Selected ongoing studies using vaccines, antibody-drug conjugates, or engineered T-cell therapies in the treatment of cervical cancer
| NCT identifier | Title | Phase | Planned enrollment | Primary endpoint(s) |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) | III | 482 | Overall survival |
| NCT04646005 | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First-Line Chemotherapy | II | 103 | Objective response rate |
| NCT04580771 | A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3–IVA Cervical Cancer, the IMMUNOCERV Trial | II | 35 | Grade 3+ acute toxicity |
| NCT04405349 | Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer | II | 50 | Adverse events, overall response rate |
| NCT03444376 | The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer | I/II | 60 | Overall response rate |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | I/II | 180 | Overall response rate |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | I/II | 150 | Overall response rate and progression-free survival |
| NCT02379520 | HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA) | I | 32 | Dose-limiting toxicity |
| NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | I | 10 | Adverse effects |
| NCT03578406 | HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer | I | 20 | Maximum tolerated dose |